Regulation of cerebroside sulfotransferase activity in cultured oligodendrocytes: effect of growth factors and insulin.
Cerebroside sulfotransferase (EC 2.8.2.11, CST) specific activity has been determined in oligodendrocyte (OL)-enriched glial cell cultures from newborn rat brain grown in serum supplemented medium. This activity is detectable at 5 days in vitro (DIV) and reaches its maximum value at 12 DIV. This period corresponds to that of oligodendrocyte precursor proliferation in these cultures. The activity decreases thereafter and remains nearly constant after 24 DIV. The developmental curve of CST activity is parallel in pure oligodendrocyte subcultures but twice higher than in primary cultures. These data confirm that CST is highly enriched in OL. Basic fibroblast growth factor (bFGF) (15 ng/ml) and platelet derived growth factor (PDGF) (0.75 U/ml) both enhance CST activity by 90% and 72%, respectively. This increase is in the same range than that of DNA content in treated cultures, whereas protein increase is smaller (50% and 22%, respectively). In contrast, transforming growth factor beta 1 (TGF beta 1, 0.5 and 5 ng/ml) does not significantly enhance CST activity nor DNA content of OL cultures. Insulin at high concentrations (5 micrograms/ml) also enhances CST activity but has no effect at physiological concentrations (20 ng/ml). These results show that CST activity can be controlled by growth factors. They suggest that CST activity is more closely related to OL and OL precursor proliferation than to myelination itself since its maximal activity preceeds myelination in vitro.
Fressinaud
C
C
Centre de Neurochimie du CNRS et U44 de l'INSERM, Strasbourg, France.
Sarliève
L L
LL
Labourdette
G
G
D000818:Animals; D002478:Cells, Cultured; D005346:Fibroblast Growth Factors / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects; D006133:Growth Substances / Q000494:pharmacology* / Q000502:physiology; D007328:Insulin / Q000494:pharmacology* / Q000502:physiology; D009836:Oligodendroglia / Q000166:cytology* / Q000187:drug effects / Q000201:enzymology; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D051381:Rats; D015238:Sulfotransferases; D013466:Sulfurtransferases / Q000235:genetics / Q000378:metabolism*; D015291:Transforming Growth Factors / Q000494:pharmacology
D006133:Growth Substances; D007328:Insulin; D010982:Platelet-Derived Growth Factor; D005346:Fibroblast Growth Factors; D015291:Transforming Growth Factors; D013466:Sulfurtransferases; D015238:Sulfotransferases; C020556:galactosylceramide sulfotransferase